Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

Clinical trial NCT06543381 · RECRUITING

Trial details

NCT number: NCT06543381
Sponsor: City of Hope Medical Center
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia Myelodysplastic Syndrome

Start date: 2025-01-17
Primary completion: 2027-02-05
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.